Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 2-Year, Phase 3 Study of the Efficacy and Safety of Lixivaptan in Participants With Autosomal Dominant Polycystic Kidney Disease Consisting of a 1-year Double-blind, Placebo-controlled, Randomized Phase and a 1-year Open-label Phase

Next Previous
Trial Profile

A 2-Year, Phase 3 Study of the Efficacy and Safety of Lixivaptan in Participants With Autosomal Dominant Polycystic Kidney Disease Consisting of a 1-year Double-blind, Placebo-controlled, Randomized Phase and a 1-year Open-label Phase

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 18 Sep 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lixivaptan (Primary)
  • Indications Autosomal dominant polycystic kidney disease
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms ACTION
  • Sponsors Palladio Biosciences

Most Recent Events

  • 13 Oct 2022 According to Eudra record, the trial has been prematurely ended in Spain, Hungary, Slovakia, Poland, and Bulgaria.
  • 02 Jun 2022 According to a Centessa Pharmaceuticals media release, the company has decided to discontinue development of lixivaptan for ADPKD including both the ACTION and the open-label ALERT Study based on a thorough reassessment of the commercial potential of lixivaptan as a potential best-in-class therapy for patients with ADPKD, and the incremental development challenges and associated costs, following a recent observation of ALT and AST elevations in one subject in the ALERT Study.
  • 02 Jun 2022 Status changed from recruiting to discontinued, according to a Centessa Pharmaceuticals media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top